rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2013-9-1-79-85rpcardio-77Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИLERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSIONАНТАГОНИСТ КАЛЬЦИЯ ТРЕТЬЕГО ПОКОЛЕНИЯ ЛЕРКАНИДИПИН: НОВЫЕ ВОЗМОЖНОСТИ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruМаксимовМ. П.MaksimovM. L.ostroumova.olga@mail.ruКопченовИ. И.KopchenovI. I.ostroumova.olga@mail.ruМосковский государственный медико-стоматологический университет им. А.И. Евдокимова; Первый Московский медицинский университет им. И.М.СеченоваРоссияMoscow State University of Medicine and Dentistry named after A.I. Evdokimov; I.M. Setchenov First Moscow State Medical UniversityRussian FederationПервый Московский медицинский университет им. И.М.СеченоваРоссияI.M. Setchenov First Moscow State Medical UniversityRussian FederationМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation201321092015917985Copyright © Ostroumova O.D., Maksimov M.L., Kopchenov I.I., 20152015Остроумова О.Д., Максимов М.П., Копченов И.И.Ostroumova O.D., Maksimov M.L., Kopchenov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/77

Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.

Приведены классификация, механизмы действия и клинические эффекты применения антагонистов кальция. Рассмотрены преимущества дигидропиридиновых антагонистов кальция третьего поколения. Подробно представлены клиническая фармакология и результаты исследований по эффективности, безопасности и органопротекции представителя дигидропиридиновых антагонистов кальция третьего поколения лерканидипина

артериальная гипертензияантигипертензивная терапияантагонисты кальциялерканидипинarterial hypertensionantihypertensive therapycalcium antagonistslercanidipineReferencesNational guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артерии альной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артерии альной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: modern aspects of cardiology. Consilium medicum 2006; 8 (11): 113–117. Russian (Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum 2006; 8 (11): 113–117).Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: modern aspects of cardiology. Consilium medicum 2006; 8 (11): 113–117. Russian (Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum 2006; 8 (11): 113–117).Preobrazhenskiy D.V., Sidorenko B.A., Dedova I.S., Shaipova A.M., Tarykina E.V. Lercanidipine – a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 14(20): 1411–1417. Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Шаипова А.М., Тарыкина Е.В. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 14(20): 1411–1417).Preobrazhenskiy D.V., Sidorenko B.A., Dedova I.S., Shaipova A.M., Tarykina E.V. Lercanidipine – a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 14(20): 1411–1417. Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Шаипова А.М., Тарыкина Е.В. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 14(20): 1411–1417).Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (suppl 1): S19–S24.Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (suppl 1): S19–S24.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.Barchielli M., Dolfini E., Farina P. et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S1–S15.Barchielli M., Dolfini E., Farina P. et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S1–S15.Testa R., Leonardi A., Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1.4-dihydropyridine calcium antagonist for hypertension. Cardiovascular Drug Reviews 1997; 15(3): 187–219.Testa R., Leonardi A., Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1.4-dihydropyridine calcium antagonist for hypertension. Cardiovascular Drug Reviews 1997; 15(3): 187–219.Omboni S, Zanchetti A, for the Multicenter Study Investigators. Antihypertensive efficacy of lercanidipine at 2.5,5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831–1838.Omboni S, Zanchetti A, for the Multicenter Study Investigators. Antihypertensive efficacy of lercanidipine at 2.5,5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831–1838.Repine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonists vs a non-calcium antagonists hypertension treatment strategy for patients with coronary artery disease. JAMA 2003; 290: 2805– 2816.Repine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonists vs a non-calcium antagonists hypertension treatment strategy for patients with coronary artery disease. JAMA 2003; 290: 2805– 2816.Ambrosioni E., Circo A. Activity of lercanidipine administrated in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. – J. Cardiovascul. Pharmacol 1997; 29(suppl 2):S16–S20.Ambrosioni E., Circo A. Activity of lercanidipine administrated in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. – J. Cardiovascul. Pharmacol 1997; 29(suppl 2):S16–S20.Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S21– S25.Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S21– S25.Romito R, Pansini MI, Perticone F et al. Comparative effect of lercandipine, felodipine and nifidipine GTIS on blood pressure and heart rate in patients with mild to moderate arterial hypertension. The Lercandipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003 J;5(4):249–53.Romito R, Pansini MI, Perticone F et al. Comparative effect of lercandipine, felodipine and nifidipine GTIS on blood pressure and heart rate in patients with mild to moderate arterial hypertension. The Lercandipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003 J;5(4):249–53.Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercandipine, lacidipine and nifedipine_GITS on blood pressure and heart rate in elderly hypertensive patients: the Elderly and LErcandipine (ELLE) study. Archives of gerontology and Geriatrics 2003; 37: 203–212.Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercandipine, lacidipine and nifedipine_GITS on blood pressure and heart rate in elderly hypertensive patients: the Elderly and LErcandipine (ELLE) study. Archives of gerontology and Geriatrics 2003; 37: 203–212.Barballo M., Sangiorgi G. B. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5):375–379.Barballo M., Sangiorgi G. B. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5):375–379.Bang LM, Chapman TM, Goa KL Lercandipine – a review of its efficacy management of hypertension. Drugs 2003; 22: 2449–2472.Bang LM, Chapman TM, Goa KL Lercandipine – a review of its efficacy management of hypertension. Drugs 2003; 22: 2449–2472.Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens 2000;18 (Suppl 2): S65.Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens 2000;18 (Suppl 2): S65.Speccia G. Saccaggi SP, Chezzi C. et al. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Current Therapeutic Research Clin Exp 2001; 62:3–15.Speccia G. Saccaggi SP, Chezzi C. et al. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Current Therapeutic Research Clin Exp 2001; 62:3–15.Cesarone M. Pressure and microcirculatory effects of treatment with lercandipine in hypertensive patients and vascular patients with hypertension. Angiol 2000; 8 (Suppl 2):S53–S63.Cesarone M. Pressure and microcirculatory effects of treatment with lercandipine in hypertensive patients and vascular patients with hypertension. Angiol 2000; 8 (Suppl 2):S53–S63.Sabbatini M., Tomassoni D., Amenta F Influence of treatment with Ca2+-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mechanisms of Ageing and Development 2001; 122: 795–809.Sabbatini M., Tomassoni D., Amenta F Influence of treatment with Ca2+-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mechanisms of Ageing and Development 2001; 122: 795–809.Vestra MD, Pozza G, Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–266.Vestra MD, Pozza G, Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–266.Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1):73–80.Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1):73–80.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S31–S35.Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S31–S35.Sangiorgi G. B. Putignano E., Calcara L., Barbagallo M. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S36–S39.Sangiorgi G. B. Putignano E., Calcara L., Barbagallo M. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S36–S39.Borghi С., Prandin M.G., Dormi A. et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000; 18 (suppl 2): S155–S156.Borghi С., Prandin M.G., Dormi A. et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000; 18 (suppl 2): S155–S156.Leonetti G., Magnani B, Pessina AC et al. Lercandipine: a long acting calcium antagonist. Results of trials in elderly hypertensive patien. J Mollecular and Cellular Cardiol 1998; 30: 254.Leonetti G., Magnani B, Pessina AC et al. Lercandipine: a long acting calcium antagonist. Results of trials in elderly hypertensive patien. J Mollecular and Cellular Cardiol 1998; 30: 254.

The authors declare that there are no conflicts of interest present.